Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 23, 2021

RedHill Biopharma to expand Covid-19 trial of opaganib to US

Specialty biopharmaceutical company RedHill Biopharma is set to expand its global Phase II/III study of opaganib in patients with severe Covid-19 to the US.

Specialty biopharmaceutical company RedHill Biopharma is set to expand its global Phase II/III study of opaganib in patients with severe Covid-19 to the US.

A novel, orally administered sphingosine kinase-2 (SK2) inhibitor, opaganib has shown antiviral, anti-inflammatory and anti-thrombotic activity and targets a human cell component involved in viral replication.

The latest move comes after the US Food and Drug Administration (FDA) reviewed the data from the US Phase II study of opaganib and issued recommendations.

RedHill noted that the expansion to the US will cause alterations to the trial protocol based on the FDA’s recommendations and ongoing talks.

The new development will aid in expediting enrolment, expanding the study to eight countries and around 40 recruiting sites, with more sites and countries on the cards.

So far, the study on 464 subjects is 50% enrolled and is anticipated to provide top-line data in the second quarter of this year.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Previously, the global Phase II/III study had undergone a DSMB futility review, which indicated that it can potentially provide a positive outcome.

Phase II data also showed no material safety differences between the opaganib and placebo treatment arms, further adding to the growing safety database for opaganib.

Recently, RedHill reported that safety and efficacy data from a non-powered US Phase II study of opaganib in patients with Covid-19 pneumonia showed greater improvement in lowering oxygen needs by end of treatment on day 14 across primary and secondary efficacy outcomes.

Furthermore, the data showed no material safety differences between opaganib and placebo treatment groups.

Last July, RedHill Biopharma submitted an application to Mexico’s COFEPRIS and initiated a filing with Brazil’s ANVISA to conduct a Phase II/III clinical trial of opaganib in hospitalised patients with severe Covid-19 pneumonia.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU